Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements - Additional Information (Detail)

v3.10.0.1
Collaboration and License Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2010
Agreement
Jun. 30, 2006
Jun. 30, 1998
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jan. 01, 2018
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price allocated to performance obligations               $ 10,000,000
Contract assets         $ 0      
Contract liabilities         0      
Contract Initiation [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price allocated to performance obligations               5,000,000
License [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price allocated to performance obligations               9,500,000
Arhalofenate Product [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price allocated to performance obligations               400,000
Research and Pre Clinical Development Services [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price allocated to performance obligations               100,000
Pharmacokinetics of Arhalofenate [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price allocated to performance obligations               $ 5,000,000
Kowa Pharmaceuticals America Inc [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Non-refundable upfront payment       $ 5,000,000        
Kowa Pharmaceuticals America Inc [Member] | Pharmacokinetics of Arhalofenate [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone payments       5,000,000        
Kowa Pharmaceuticals America Inc [Member] | Achievement of Other Specific Development and Sales [Member] | Maximum [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone payments       190,000,000        
Kowa Pharmaceuticals America Inc [Member] | Phase 3 Study [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Milestone payments       5,000,000        
Janssen Pharmaceutical NV [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Royalty payment         0 $ 0 $ 0  
Accrued royalties       $ 0 0 0 0  
Janssen Pharmaceutical NV [Member] | Maximum [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Percentage of royalty on net sales   8.00%            
Janssen Pharmaceuticals, Inc. [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Number of development and license agreements | Agreement 2              
DiaTex, Inc. [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Royalty payment         0 0 0  
Monthly license fees     $ 2,000          
Potential future development payments     $ 800,000          
Development payment         $ 0 $ 0 $ 0